Prevalence of metabolic syndrome in primary health settings in Qatar: a cross sectional study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968562 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2458 (Electronic) Linking ISSN: 14712458 NLM ISO Abbreviation: BMC Public Health Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Severity of Illness Index*; Metabolic Syndrome/*epidemiology; Adult ; Aged ; Cross-Sectional Studies ; Female ; Humans ; Male ; Metabolic Syndrome/diagnosis ; Middle Aged ; Nutrition Surveys ; Obesity/epidemiology ; Prevalence ; Qatar/epidemiology ; Risk Factors ; Socioeconomic Factors ; Waist Circumference ; Young Adult
    • Abstract:
      Background: In Qatar, prevalence of metabolic components is significantly higher compared to other countries. It is therefore urgent to understand the prevalence of metabolic syndrome (MetS) with the goal of identifying etiologic factors in Qatar. This study was undertaken to estimate the prevalence of MetS, by age, gender and nationality within primary care settings in Qatar. In addition, it determined the independent effects of risk factors on the prevalence of MetS.
      Methods: A cross-sectional study design was used. Data for individuals aged ≥18 and who visited a publicly funded primary health centre in Qatar during 2017 were extracted from electronic medical records and analysed.
      Results: The findings showed that the prevalence of individual MetS components ranged between 48.5-60.3%. Overall prevalence of MetS was 48.8% (N = 62,492) in the study population. Prevalence of MetS increased with age. 50.3% of the population within the 40-49 year age group had MetS. In this age band, individuals were 5.1 times more likely of having MetS compared to the 18-29 year age group. MetS was slightly more prevalent in men (56 .7%) compared to women (42.5%). However, men were 1.33 times more likely of having MetS compared to women. The prevalence of MetS ranged between 20.6 - 60% across nationalities. It was most prevalent in Southern Asians (60%), followed by Northern Africans (50.7%) and Western Asians (excluding Qatar) (46.8%). Prevalence of MetS in Qataris was 43%. Southern Asians, Northern African and Western Asians were 1.73, 1.38 and 1.17 more likely to have MetS compared to Qataris.
      Conclusions: The study provides essential epidemiological information required by decision makers. Although not nationally representative, this study is suggestive of a higher prevalence of MetS among a younger population, men and in Southern Asian, Northern African and Western Asian nationalities. Prevention, treatment and control of MetS is a public health problem in Qatar. More studies are needed to establish which public health interventions are likely to be effective in Qatar.
    • References:
      Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2307-17. (PMID: 20826833)
      BMJ Nutr Prev Health. 2019 May 17;2(1):20-29. (PMID: 33235953)
      Gynecol Oncol. 2012 May;125(2):330-5. (PMID: 22330614)
      Rev Diabet Stud. 2006 Fall;3(3):118-26. (PMID: 17487335)
      Dis Model Mech. 2009 May-Jun;2(5-6):231-7. (PMID: 19407331)
      BMC Cancer. 2014 Feb 18;14:103. (PMID: 24548688)
      Lancet. 2014 Aug 30;384(9945):766-81. (PMID: 24880830)
      Int J Cancer. 2012 Jul 1;131(1):193-200. (PMID: 21805476)
      Prev Chronic Dis. 2017 Mar 16;14:E24. (PMID: 28301314)
      Circulation. 2005 Oct 25;112(17):2735-52. (PMID: 16157765)
      Ann Hematol. 2012 Oct;91(10):1519-31. (PMID: 22588328)
      BMC Med. 2011 May 05;9:48. (PMID: 21542944)
      Int J Chronic Dis. 2017;2017:8765804. (PMID: 28293668)
      J Am Coll Cardiol. 2010 Sep 28;56(14):1113-32. (PMID: 20863953)
      Diabetes Care. 2005 Jul;28(7):1769-78. (PMID: 15983333)
      Cancer Causes Control. 2011 May;22(5):743-51. (PMID: 21380729)
      Diabet Med. 2010 May;27(5):593-7. (PMID: 20536958)
      Clin Endocrinol (Oxf). 2008 May;68(5):730-7. (PMID: 17980012)
      Cardiol Res Pract. 2014;2014:943162. (PMID: 24711954)
      Obes Rev. 2015 Jan;16(1):1-12. (PMID: 25407540)
      Int J Epidemiol. 2015 Aug;44(4):1353-63. (PMID: 25652574)
      Eur J Epidemiol. 2010 Jun;25(6):375-84. (PMID: 20425137)
      BMJ Open. 2016 Sep 06;6(9):e009514. (PMID: 27601485)
      Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1737-45. (PMID: 20615887)
      Dan Med Bull. 2007 May;54(2):157-9. (PMID: 17521535)
      Prev Med Rep. 2017 Jul 19;7:211-215. (PMID: 28794957)
      Physiology (Bethesda). 2017 Jan;32(1):9-19. (PMID: 27927801)
      PLoS One. 2014 Sep 22;9(9):e107294. (PMID: 25244618)
      PLoS One. 2014 Feb 21;9(2):e89368. (PMID: 24586723)
      Metab Syndr Relat Disord. 2009 Jun;7(3):221-9. (PMID: 19320557)
      Diabetes Metab Syndr. 2018 Apr - Jun;12(2):195-201. (PMID: 29203060)
    • Contributed Indexing:
      Keywords: Dyslipidaemia diabetes; Hypertension; Metabolic syndrome; Obesity; Prevalence; Primary care; Qatar
    • Publication Date:
      Date Created: 20200505 Date Completed: 20200916 Latest Revision: 20240328
    • Publication Date:
      20240329
    • Accession Number:
      PMC7196222
    • Accession Number:
      10.1186/s12889-020-08609-5
    • Accession Number:
      32362284